Critical appraisal:Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, et al 2008 2

Risk of bias assessment: randomised controlled trial

Was the trial double-blinded?

Outcomes not blinded, substantial side-effects, or not reported.

Was the treatment allocation schedule concealed?

No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).

Were all randomised participants included in the analysis?

Too many exclusions, differential loss in comparison groups, or not reported.

The field below is not considered when calculating the risk of bias rating

How was the allocation schedule generated?

Inadequate or not reported

Overall risk of bias

High risk of bias

Additional comments: Please replace this text and include any additional comments in regards to your quality rating

Comments

The quality was assessed for the outcome of adverse events.

This appraisal has been completed.

Article

Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis 2008;11(2):134-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17533394.

Assigned to

User:Cindy.peng

Topic area

Guidelines:PSA Testing/Biopsy

Clinical question

• For men undergoing an initial prostate biopsy how many biopsy cores, which pattern of biopsy sampling sites and which approach constitute an adequate prostate biopsy?

Form

Form:Quality appraisal rct

Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment